Shareholder’s Alert on Worth Watching Stocks: NorthStar Asset Administration Group Inc (NYSE:NSAM), Biogen Inc (NASDAQ:BIIB)

On Thursday, Shares of NorthStar Asset Administration Group Inc (NYSE:NSAM), added 0.22% and closed at $13.54 in the last trading session. The last trading range of the stock ranges between $13.24 and $13.70. NorthStar Real Estate Income II, Inc. (NorthStar Income II) declared that it priced a $284.2 million non-recourse, match-term, non-mark-to-market financing transaction in the form of a commercial mortgage-backed securitization (CMBS), NorthStar 2016-1, at a weighted average cost of funds of LIBOR + 2.07% and an advance rate of 68% ($193 million of investment grade bonds issued and sold). The transaction is collateralized by a pool of 10 commercial real estate mortgage loans, all but one of which was directly originated by NorthStar Income II and three senior participations originated by NorthStar Real Estate Income Trust, Inc. (NorthStar Income).  NorthStar Income II contributed about $254.7 million of collateral to the transaction, and NorthStar Income contributed about $29.5 million of collateral to the transaction. The transaction closed on November 9, 2016.

Biogen Inc (NASDAQ:BIIB), jumped 1.42% and closed at $324.40 in the last trading session. The last trading range of the stock ranges between $319.49 and $329.83. The company’s Market capitalization is $76.37 Billion with the total Outstanding Shares of 217.57 million. Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders. It offers TECFIDERA, AVONEX, and PLEGRIDY to treat relapsing forms of multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn’s disease; and FAMPYRA to improve walking ability for patients with MS. The company also provides ELOCTATE to treat adults and children with hemophilia A for control of bleeding episodes; ALPROLIX to treat adults and children with hemophilia B for control of bleeding episodes; RITUXAN for treating non-Hodgkin’s lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), in addition to two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with formerly untreated CLL; and FUMADERM to treat plaque psoriasis. The company’s products in Phase III development stage comprise ZINBRYTA, a monoclonal antibody for the treatment of relapsing-remitting MS; Aducanumab for Alzheimer’s disease; and ISIS-SMNRx for spinal muscular atrophy. Its Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Amiselimod for multiple autoimmune indications; BAN2401 and E2609 for Alzheimer’s disease; Raxatrigine for trigeminal neuralgia; rAAV-XLRS for X-linked juvenile retinoschisis; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise Dapirolizumab pegol for systemic lupus erythematosus (SLE); ISIS – DMPK for myotonic dystrophy; Anti-BDCA2 for SLE; Anti-alpha-synuclein for Parkinson’s disease; and BIIB063 for sjogren’s syndrome.

Leave a Reply

Your email address will not be published. Required fields are marked *